NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year
The factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved a major talking point at an event on the fringes of this year’s ESMO conference
Bristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after surgery for skin cancer.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.